tradmap

STRO Sutro Biopharma, Inc.

$29.68 +4.05%

Healthcare · Biological Products, (No Diagnostic Substances)

Sutro Biopharma, Inc. (STRO) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $492 million. Shares last traded at $29.68, 30.0% below their 52-week high. Over the past year the stock is up 3633.2%. Net profit margin is -186.4%, below the peer median of 6.3%. Revenue grew 65.2% year over year.

Market Cap
$492M
Shares Out
16.6M
EPS (TTM)
$-14.77
P/E Ratio
P/S Ratio
4.80
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$42.38
52-Week Low
$0.67
Volume
16,989
Avg Vol (3m)
15,356.302

Performance

1W
+12.19%
1M
-6.12%
3M
+40.77%
6M
+200.35%
YTD
+170.02%
1Y
+3633.17%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.87
SMA (50)
$31.79
SMA (200)
$15.37
Price vs SMA50
-6.66%
Price vs SMA200
+93.11%
ATR (14)
$2.89

Financials

Revenue
$102M
Net Income
$-191M
Gross Margin
Operating Margin
-154.5%
Net Margin
-186.4%
Return on Equity
285.6%
Return on Assets
-78.9%
Current Ratio
3.12
Debt / Equity
-0.06
Revenue Growth (YoY)
+65.2%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-2.94 2026-05-14
FY 2025 $-22.49 2026-03-23
Q3 2025 $-1.71 2025-11-06
Q2 2025 $-1.04 2025-08-07
Q1 2026 $-9.08 2026-05-14
FY 2025 $-29.40 2026-03-23

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

STRO vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
4.80 / 5.21 med
-8% discount
Net margin vs peers
-186.4% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.